Cambridge biotech Acceleron to be acquired by Merck for $11.5B

A major pharmaceutical company has agreed to pay $11.5 billion in cash for Cambridge-based Acceleron, which is developing drugs for blood disorders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.